Positron Emission Tomography (PET) Scanners Market Size, Share and Forecast 2026 to 2035
Share With :
Positron Emission Tomography (PET) Scanners Market Size is valued at USD 1.48 Bn in 2025 and is predicted to reach USD 2.51 Bn by the year 2035 at a 5.7% CAGR during the forecast period for 2026 to 2035.
Positron Emission Tomography (PET) Scanners Market Size, Share & Trends Analysis Distribution by Detector Type (Bismuth Germanium Oxide, Lutetium Fine Silicate, Gadolinium Oxyorthosilicate, Lutetium Oxyorthosilicate, and Lutetium Yttrium Orthosilicate), Product Type (Full-ring PET Scanner and Partial-ring PET Scanner), Application (Oncology, Cardiology, Neurology, and Others), End-user (Hospitals, PET Centers, Diagnostic Centers, and Research Institute), and Segment Forecasts, 2026 to 2035
-Scanners-Market-info.webp "Positron Emission Tomography (PET) Scanners Market info")
Over the past few decades, few imaging techniques have reshaped clinical decision-making in oncology and neurology as profoundly as positron emission tomography (PET). PET scanners are sophisticated nuclear medicine devices that visualize and quantify metabolic, biochemical, and molecular processes in vivo by detecting pairs of 511 keV annihilation photons produced when positrons emitted from short-lived radioisotopes (most commonly ¹⁸F-FDG) collide with electrons in tissue.
The resulting coincidence events are reconstructed into three-dimensional tomographic images that reveal regional tracer uptake, distribution, and clearance—information that reflects tissue function rather than merely anatomical structure. Widely regarded as the gold standard for staging and restaging many cancers, assessing myocardial viability, evaluating neurological disorders, and monitoring treatment response, modern PET systems are almost invariably hybridised with CT (PET/CT) or MRI (PET/MRI) to provide precise anatomical correlation and attenuation correction. Ongoing technological progress—higher-sensitivity time-of-flight detectors, extended axial field-of-view designs, fully digital silicon photomultipliers, and novel tracers targeting specific receptors or pathways—continues to expand the clinical utility and diagnostic power of PET imaging.
The positron emission tomography (PET) scanners market is expanding due in part to the growing need for PET analysis in radiopharmaceuticals. Additionally, the aging of the population in both developed and emerging countries will significantly boost the positron emission tomography (PET) scanners market's expansion. Because of the physiological changes brought on by aging, people are more susceptible to chronic illnesses including diabetes, heart disease, and stroke.
Throughout the projected period, the market may rise due to ongoing technological developments in PET scanner quality and improvement, which produce high-resolution images. Additionally, the positron emission tomography (PET) scanners market has grown as a result of growing trends in tailored medicine. PET imaging is appropriate for targeted treatment since it offers excellent resolution regarding tracer uptake and disease symptoms. Furthermore, the positron emission tomography (PET) scanners market in hospitals and diagnostic centers is expanding due to growing healthcare expenses and the necessity for favorable reimbursement systems in developed nations. However, the high expenses of running PET scanners and the availability of radiotracers in particular regions present some obstacles to the growth of the market.
• Siemens Healthineers
• GE Healthcare
• Koninklijke Philips N.V.
• Hitachi Medical Corporation
• Yangzhou Kindsway Biotech Co. Ltd
• Toshiba Corporation
• Mediso Ltd.
• Canon Medical Systems Corporation
• Oncovision
• Positron Corporation
• Others
One of the main factors influencing the need for positron emission tomography (PET) scanners is the rising incidence of chronic illnesses like cancer, neurological conditions, and heart ailments worldwide. According to the American Cancer Society, there will likely be 609,820 cancer-related deaths and 1,958,310 new cancer cases in the US in 2023. PET imaging is perfect for early disease detection because it makes metabolic and physiological processes visible.
It offers useful information that other imaging techniques, such as CT or MRI, are unable to provide, enabling better treatment choices. Additionally, PET scans aid in cancer identification, staging, biopsy guiding, and therapy monitoring in oncology. FDG-PET is frequently used to evaluate the course of lymphoma and lung cancer, providing improved clinical outcomes through accurate tumor localization. PET is essential in neurology for identifying conditions like Alzheimer's before outward signs show. Moreover, healthcare institutions are implementing PET scanners more quickly due to aging populations and increased awareness of preventative treatment.
One of the main obstacles to the widespread use of positron emission tomography (PET) scanners is their exorbitant cost, which frequently exceeds one million dollars per unit. For instance, Siemens Biograph Vision and other sophisticated hybrid PET/CT systems are expensive to purchase and install. The whole financial burden is further increased by operating costs including shielding infrastructure, equipment maintenance, and radiotracer manufacture. Additionally, facilities have to depend on radiopharmaceutical suppliers or invest in cyclotrons, which raises handling and logistics expenses. Furthermore, small hospitals and diagnostic facilities find it difficult to defend or pay for these costs, particularly in environments with limited resources. Patients and healthcare professionals are further deterred from using PET imaging by inconsistent reimbursement schemes and incomplete coverage. Innovative low-cost PET solutions, scalable methods, and encouraging reimbursement schemes are needed to overcome these financial obstacles.
In 2025, the oncology category dominated the Positron Emission Tomography (PET) Scanners market due to the increasing number of cancer occurrences worldwide. According to WHO figures, an estimated 19 million new instances of cancer are recorded each year, making it one of the top causes of death globally. For cancer to be successfully managed, an early and precise diagnosis is essential.
High sensitivity and specificity are made possible by PET imaging that uses radionuclides like fluorodeoxyglucose (FDG) to detect primary cancers and metastases. PET has expanded its clinical relevance for diagnostic, staging, and restaging purposes across a variety of cancer types due to its capacity to map tumor metabolism at the cellular level. Additionally, PET helps track tumor recurrence and measure chemotherapy response. Cancer incidence will soon rise as a result of an aging population and other cancer risk factors including obesity and inactivity.
The hospitals category held the largest share in the Positron Emission Tomography (PET) Scanners market in 2025. Their strong medical infrastructure, which for the easy integration of cutting-edge diagnostic technology like PET imaging, is the source of their leadership. These facilities work as the main centers for the diagnosis and treatment of complicated problems in the domains of neurology, cardiology, and oncology.
PET scanners are essential for identifying neurological abnormalities, assessing heart function, detecting metabolic activity, and staging cancer. PET scanners are vital equipment because of the growing patient volume in hospitals, which increases the need for accurate and quick diagnostic instruments. Furthermore, hospitals frequently participate in clinical research and drug development studies, which increases the demand for precision imaging technology to help make evidence-based decisions. The precision and effectiveness of diagnoses are improved by their capacity to invest in state-of-the-art machinery and qualified staff.
The Positron Emission Tomography (PET) Scanners market was dominated by North America region in 2025 due to the region's well-established healthcare systems, high healthcare spending, significant influence from major medical technology companies, increased R&D activity, widespread use of advanced imaging technologies, and elevated risks of cancer and cardiovascular disease in patients.
The U.S. positron emission tomography (PET) scanners market is distinguished by quick product releases and innovation aimed at enhancing image quality and cutting scan times. Furthermore, the region's positron emission tomography (PET) scanners market is expanding due to a number of programs, government and non-government healthcare infrastructure, and reimbursement. Additionally, collaborations between tech companies and medical institutions support studies into novel radiotracers that more precisely target particular illnesses, increasing the range of clinical uses.
-Scanners-Market-region.webp "Positron Emission Tomography (PET) Scanners Market region")
February 2025: Siemens Healthineers and Cubresa, a Canadian medical imaging business that specializes in brain PET scanner, performed a strategic partnership. Through this collaboration, Cubresa advancing and guarantee that its BrainPETTM scanner is compatible with Siemens MAGNETOM MRI systems in any field strength, allowing for simultaneous PET/MR imaging for improved brain diagnosis. Siemens Healthineers is a medical technology firm with headquarters in Germany that specializes in healthcare solutions, diagnostics, and imaging.
| Report Attribute | Specifications |
| Market size value in 2025 | USD 1.48 Bn |
| Revenue forecast in 2035 | USD 2.51 Bn |
| Growth Rate CAGR | CAGR of 5.7% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Detector Type, Product Type, Application, End-user, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Siemens Healthineers, GE Healthcare, Koninklijke Philips N.V., Hitachi Medical Corporation, Yangzhou Kindsway Biotech Co. Ltd, Toshiba Corporation, Mediso Ltd., Canon Medical Systems Corporation, Oncovision, Positron Corporation, and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
• Bismuth Germanium Oxide
• Lutetium Fine Silicate
• Gadolinium Oxyorthosilicate
• Lutetium Oxyorthosilicate
• Lutetium Yttrium Orthosilicate
-Scanners-Market-seg.webp "Positron Emission Tomography (PET) Scanners Market seg")
• Full-ring PET Scanner
• Partial-ring PET Scanner
• Oncology
• Cardiology
• Neurology
• Others
• Hospitals
• PET Centers
• Diagnostic Centers
• Research Institute
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.